ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

ClinicalTrials.gov ID: NCT01894061

Public ClinicalTrials.gov record NCT01894061. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 17, 2026, 3:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma

Study identification

NCT ID
NCT01894061
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Case Comprehensive Cancer Center
Other
Enrollment
25 participants

Conditions and interventions

Interventions

  • Bevacizumab Biological
  • NovoTTF-l00A Device
  • Quality of Life Assessment Other

Biological · Device · Other

Eligibility (public fields only)

Age range
22 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 17, 2013
Primary completion
Jun 30, 2019
Completion
Jun 30, 2019
Last update posted
Feb 16, 2025

2013 – 2019

United States locations

U.S. sites
3
U.S. states
1
U.S. cities
2
Facility City State ZIP Site status
University of Cincinnati Cincinnati Ohio 45220
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland Ohio 44106
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center Cleveland Ohio 44195

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01894061, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 16, 2025 · Synced May 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01894061 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →